{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:16:30Z","timestamp":1790702190041,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German Center"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Alectinib is a standard initial treatment for patients with advanced anaplastic lymphoma kinase (ALK) rearranged non-small-cell lung cancer (NSCLC). The current study analyzed a prospective cohort of 24 consecutive alectinib-treated patients and controls in order to comprehensively characterize longitudinal erythrocyte changes under treatment with ALK inhibitors. Upon starting alectinib, all examined patients developed reticulocytosis and abnormal erythrocyte morphology with anisocytosis and a predominance of acanthocytes (64% of red blood cells on average, range 36\u2013100%) in the peripheral blood smear within approximately 2 weeks. Changes were accompanied by a gradual reduction in Eosin-5-maleimide (EMA) binding, which became pathologic (&lt;80% of cells) within 1\u20132 months in all cases, mimicking an abortive form of hereditary spherocytosis. The latter could be ruled out in 3\/3 of analyzed cases by normal sequencing results for the ANK1, EPB42, SLC4A1, SPTA1, or SBTB genes. The direct Coombs test was also negative in 11\/11 tested cases. Besides, anemia, increased LDH, and increased bilirubin were noted in a fraction of patients only, ranging between 42 and 68%. Furthermore, haptoglobin decreases were infrequent, occurring in approximately 1\/3 of cases only, and mild, with an average value of 0.93 g\/L within the normal range of 0.3\u20132 g\/dL, suggesting that hemolysis occurred predominantly in the extravascular compartment, likely due to splenic trapping of the deformed erythrocytes. These changes showed no association with progression-free survival under alectinib or molecular features, i.e., ALK fusion variant or TP53 status of the disease, and resolved upon a switch to an alternative ALK inhibitor. Thus, alectinib induces mild, reversible erythrocyte changes in practically all treated patients, whose most sensitive signs are aberrant red cell morphology in the peripheral smear, a pathologic EMA test, and reactive reticulocytosis. Frank hemolytic anemia is rare, but mild subclinical hemolysis is very frequent and poses differential-diagnostic problems. Alectinib can be continued under the regular control of hemolysis parameters, but the risk of long-term complications, such as cholelithiasis due to increased serum bilirubin in most patients, remains unclear at present.<\/jats:p>","DOI":"10.3390\/cancers14112720","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T05:25:42Z","timestamp":1653974742000},"page":"2720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib"],"prefix":"10.3390","volume":"14","author":[{"given":"Julia","family":"Kunz","sequence":"first","affiliation":[{"name":"Department of Thoracic Oncology, Heidelberg University Hospital, 69126 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Wiedemann","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Heidelberg University Hospital, 69126 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidrun","family":"Grosch","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Heidelberg University Hospital, 69126 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Kriegsmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology\/Oncology\/Rheumatology), Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Gryzik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology\/Oncology\/Rheumatology), Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8888-6824","authenticated-orcid":false,"given":"Julia","family":"Felden","sequence":"additional","affiliation":[{"name":"Hematology Laboratory MVZ, 64646 Heppenheim, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hundemer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine V (Hematology\/Oncology\/Rheumatology), Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huriye","family":"Seker-Cin","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Stenzinger","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Leo","sequence":"additional","affiliation":[{"name":"Institute of Immunology, Heidelberg University Hospital, 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[{"name":"Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany"},{"name":"Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9511-055X","authenticated-orcid":false,"given":"Michael","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Heidelberg University Hospital, 69126 Heidelberg, Germany"},{"name":"Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7966-8980","authenticated-orcid":false,"given":"Petros","family":"Christopoulos","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Heidelberg University Hospital, 69126 Heidelberg, Germany"},{"name":"Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), 69120 Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","article-title":"Toward Personalized Treatment Approaches for Non-small-Cell Lung Cancer","volume":"27","author":"Wang","year":"2021","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.20.03570","article-title":"Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update","volume":"39","author":"Hanna","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic Non-small Cell Lung Cancer: Esmo Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_4","unstructured":"Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E.F., Faivre-Finn, C., Mok, T.S., Reck, M., van Schil, P.E., and Hellmann, M.D. (2021, April 18). ESMO Clinical Practice Living Guidelines\u2014Metastatic Non-Small-Cell Lung Cancer. Available online: https:\/\/www.esmo.org\/guidelines\/lung-and-chest-tumours\/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Gristina, V., La Mantia, M., Iacono, F., Galvano, A., Russo, A., and Bazan, V. (2020). The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120474"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","article-title":"Updated Overall Survival and Final Progression-Free Survival Data for Patients with Treatment-Naive Advanced ALK-Positive Non-Small-Cell Lung Cancer in the ALEX Study","volume":"31","author":"Mok","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2146\/ajhp170266","article-title":"Alectinib for advanced ALK-positive non-small-cell lung cancer","volume":"75","author":"Ly","year":"2018","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification","volume":"10","author":"Travis","year":"2015","journal-title":"J. Thor. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/ijc.32133","article-title":"Combined Targeted DNA and RNA Sequencing of Advanced NSCLC in Routine Molecular Diagnostics: Analysis of the First 3000 Heidelberg Cases","volume":"145","author":"Volckmar","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/ijlh.12794","article-title":"Flow Cytometric Osmotic Fragility Test and Eosin-5\u2019-Maleimide Dye-Binding Tests Are Better than Conventional Osmotic Fragility Tests for the Diagnosis of Hereditary Spherocytosis","volume":"40","author":"Arora","year":"2018","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"613559","DOI":"10.3389\/fphys.2020.613559","article-title":"Genetics and Genomics Approaches for Diagnosis and Research into Hereditary Anemias","volume":"11","author":"Russo","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"v651","DOI":"10.1093\/annonc\/mdz260.103","article-title":"Comparison of Real-World Response Rate (rwRR) to RECIST-Based Response Rate in Patients with Advanced Non-small Cell Lung Cancer (aNSCLC)","volume":"30","author":"Ma","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"P3-17-03","DOI":"10.1158\/1538-7445.SABCS17-P3-17-03","article-title":"Concordance of Real World Progression Free Survival (PFS) on Endocrine Therapy as First Line Treatment for Metastatic Breast Cancer Using Electronic Health Record with Proper Quality Control versus Conventional PFS from a Phase 3 Trial","volume":"78","author":"Bartlett","year":"2018","journal-title":"Cancer Res."},{"key":"ref_18","first-page":"3","article-title":"Cancer-Related Anemia: Its Causes and Characteristics","volume":"21","author":"Spivak","year":"1994","journal-title":"Semin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and Laboratory Features of Autoimmune Hemolytic Anemia Associated with Immune Checkpoint Inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_20","unstructured":"Therapeutic Goods Administration, Australian Department of Health (2022, April 19). AusPAR Alecensa Alectinic hydrochloride Roche Products Pty Limited PM-2015-04677-1-4, Available online: https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-alectinib-hydrochloride-171127.pdf."},{"key":"ref_21","first-page":"335","article-title":"An Unusual Cause of Anemia in Cirrhosis: Spur Cell Anemia, a Case Report with Review of Literature","volume":"9","author":"Privitera","year":"2016","journal-title":"Gastroenterol. Hepatol. Bed Bench"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood-2019-01-897892","article-title":"Acanthocytosis Causing Chronic Hemolysis in a Patient with Advanced Cirrhosis","volume":"133","author":"Marks","year":"2019","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"635670","DOI":"10.1155\/2015\/635670","article-title":"Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia","volume":"2015","author":"Barcellini","year":"2015","journal-title":"Dis. Markers"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"103103","DOI":"10.1016\/j.ebiom.2020.103103","article-title":"Longitudinal Therapy Monitoring of ALK-Positive Lung Cancer by Combined Copy Number and Targeted Mutation Profiling of Cell-Free DNA","volume":"62","author":"Dietz","year":"2020","journal-title":"EBioMedicine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.pathol.2020.10.023","article-title":"Alectinib Induces Marked Red Cell Spheroacanthocytosis in a Near-Ubiquitous Fashion and Is Associated with Reduced Eosin-5-Maleimide Binding","volume":"53","author":"Kuzich","year":"2021","journal-title":"Pathology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12308-020-00427-3","article-title":"A Multi-Centre Case Series of Alectinib-Related Erythrocyte Membrane Changes and Associated Haemolysis","volume":"14","author":"Gullapalli","year":"2021","journal-title":"J. Hematopathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ijc.31893","article-title":"Identification of a Highly Lethal V3+ TP53+ Subset in ALK+ Lung Adenocarcinoma","volume":"144","author":"Christopoulos","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S1989","DOI":"10.21037\/jtd.2018.05.61","article-title":"EML4-ALK V3, Treatment Resistance, and Survival: Refining the Diagnosis of ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2018","journal-title":"J. Thor. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Elsayed, M., and Christopoulos, P. (2021). Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020080"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.18632\/oncotarget.26886","article-title":"Defining Molecular Risk in ALK+ NSCLC","volume":"10","author":"Christopoulos","year":"2019","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0016-5085(52)80125-8","article-title":"Incidence of Gallbladder Disease in Chronic Hemolytic Anemia (Spherocytosis)","volume":"21","author":"Bates","year":"1952","journal-title":"Gastroenterology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3816\/CLC.2003.n.022","article-title":"Anemia in Lung Cancer: Clinical Impact and Management","volume":"5","author":"Pirker","year":"2003","journal-title":"Clin. Lung Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:22:27Z","timestamp":1760138547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/11\/2720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":32,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["cancers14112720"],"URL":"https:\/\/doi.org\/10.3390\/cancers14112720","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]}}}